Navigation Links
Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Date:4/20/2012

EAST BRUNSWICK, N.J., April 20, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's first quarter financial results will be released prior to the open of the market on Wednesday, May 9, 2012.
Savient executive management will host a conference call beginning at 9:00 a.m. Eastern Time on May 9, 2012, to discuss these results and to answer questions.

To participate by telephone, please dial 866-393-1565 (Domestic) or 253-237-1151 (International). The conference ID number is 72346185.  The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.  A telephone replay will be available from 12:00 p.m. Eastern Time on May 9, 2012, through 12:00 a.m. Eastern Time on May 16, 2012, by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 72346185.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT-IContact: Mary Coleman

Carney Noensie Savient Pharmaceuticals, Inc.

Burns McClellan information@savient.com

cnoensie@burnsmc.com (732) 418-9300

(212) 213-0006


'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Imperial Capital Healthcare Investor Forum
2. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results
3. Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
4. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
5. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
6. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
7. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
8. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
9. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
10. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
11. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  While Abbott,s announced ... the company,s valve repair and stent business, healthcare ... places Abbott more firmly into patient monitoring.  Kalorama ... fastest growing device areas, with double-digit growth expected ... report,  Advanced Remote Patient Monitoring . ...
(Date:4/28/2016)... TOKYO , April 28, 2016 /PRNewswire/ ... Ahuja , George Phillips und ... wachsenden Unternehmens    ArisGlobal®, ein ... Life Sciences, gab heute bekannt, dass neue ... wachsenden Unternehmens gestoßen sind, die vielfältige Erfahrungen ...
(Date:4/28/2016)... , Net Sales of $1.90 billion represent an increase of ... and an increase of 1.2% on an adjusted pro forma, ... quarter were $0.52 reported, a decrease of 47.5% from the ... over the prior year period , The Company increases ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... Dr. Bernie Siegel, (M.D.) world ... and MIRACLES") addresses touchy topics related to Death live on Dr. Carol ... Bernie Siegel, author of a plethora of essential books-to-read for physicians and all ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart is celebrating its grand ... in the Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. There will ... Plus attendees will have the opportunity to meet general dentists Thomas Richards, DDS, and ...
(Date:4/29/2016)... PA (PRWEB) , ... April 29, 2016 , ... ... announced that student team BioCellection won the $30,000 Perlman Grand Prize of the ... Prize, the Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee ...
(Date:4/29/2016)... ON (PRWEB) , ... April 29, 2016 , ... ... and the Canadian Celiac Association (CCA), is pleased to announce the launch of ... gluten-free products, nutritional articles, recipes, and more. The purpose of the GFCP ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. Majid ... effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this permanent ... that involves one or both jaw bones. This surgery is performed to correct the alignment ...
Breaking Medicine News(10 mins):